Pivotal Therapeutics Inc. (PVTTF)
-OTC Markets 0.15 
0.00(1.31%) May 17, 3:49PM EDT
| Prev Close: | 0.15 |
|---|
| Open: | 0.15 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.15 - 0.15 |
|---|
| 52wk Range: | N/A |
|---|
| Volume: | 13,500 |
|---|
| Avg Vol (3m): | N/A |
|---|
| Market Cap: | 12.00M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.04 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Pivotal Therapeutics VASCAZEN®-REVEAL trial meets primary and secondary endpoints - VASCAZEN® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)PR Newswire(Tue, May 7)
- Pivotal Therapeutics VASCAZEN®-REVEAL trial meets primary and secondary endpoints - VASCAZEN® shows 121% correction of an Omega-3 deficiency (p< 0.0001) with a concomittant 48% reduction in triglycerides (p<0.0005)CNW Group(Tue, May 7)
- Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee MedalCNW Group(Thu, May 2)
- Pivotal's Founder and Chairman Dr. George Jackowski receives Queen Elizabeth II Diamond Jubilee MedalPR Newswire(Thu, May 2)
- Pivotal Therapeutics VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific SessionsCNW Group(Tue, Apr 30)
- Pivotal Therapeutics VASCAZEN® - REVEAL Trial Top Line Results to be presented at American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology 2013 Scientific SessionsPR Newswire(Tue, Apr 30)
- Pivotal Therapeutics Announces 2012 Financial ResultsCNW Group(Mon, Apr 29)
- Pivotal Therapeutics Announces 2012 Financial ResultsPR Newswire(Mon, Apr 29)
- Pivotal Progresses with VascazenZacks(Tue, Apr 16)
- Pivotal Therapeutics VASCAZEN® - Meets Primary Endpoint in Reveal Trial - Top Line Results Accepted for Presentation at the American Heart Association's ATVB 2013 Scientific SessionsCNW Group(Tue, Apr 9)
- Pivotal Therapeutics VASCAZEN® - Meets Primary Endpoint in Reveal Trial - Top Line Results Accepted for Presentation at the American Heart Association's ATVB 2013 Scientific SessionsPR Newswire(Tue, Apr 9)
- Pivotal Therapeutics Exhibiting at the American College of Cardiology's 62nd Annual Scientific Session and EXPOCNW Group(Wed, Mar 6)
- Pivotal Therapeutics Exhibiting at the American College of Cardiology's 62nd Annual Scientific Session and EXPOPR Newswire(Wed, Mar 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 313.09 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pivotal Therapeutics Inc., a development stage specialty pharmaceutical company, focuses on providing pharmaceutical products for the treatment of cardiovascular diseases.
View More